.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Argus Health
Cipla
Express Scripts
Boehringer Ingelheim
AstraZeneca
Cantor Fitzgerald
US Army
US Department of Justice
McKinsey

Generated: November 19, 2017

DrugPatentWatch Database Preview

SAVAYSA Drug Profile

« Back to Dashboard

What is the patent landscape for Savaysa, and what generic Savaysa alternatives are available?

Savaysa is a drug marketed by Daiichi Sankyo Inc and is included in one NDA. There are two patents protecting this drug.

This drug has eighty-five patent family members in twenty-eight countries and seven supplementary protection certificates in six countries.

The generic ingredient in SAVAYSA is edoxaban tosylate. One supplier is listed for this compound. Additional details are available on the edoxaban tosylate profile page.

Summary for SAVAYSA

Pharmacology for SAVAYSA

Drug ClassFactor Xa Inhibitor
Mechanism of ActionFactor Xa Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-001Jan 8, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-003Jan 8, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-002Jan 8, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-003Jan 8, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-001Jan 8, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-001Jan 8, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-002Jan 8, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-002Jan 8, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-003Jan 8, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SAVAYSA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,342,014Diamine derivatives► Subscribe
9,707,296Pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SAVAYSA

Country Document Number Estimated Expiration
Norway2015022► Subscribe
TaiwanI409064► Subscribe
Malaysia149356► Subscribe
BrazilPI0809205► Subscribe
Taiwan200845972► Subscribe
TaiwanI298066► Subscribe
China100545160► Subscribe
Israel200790► Subscribe
Australia2002328596► Subscribe
Japan4463875► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SAVAYSA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0760Netherlands► SubscribePRODUCT NAME: EDOXABAN, EEN ZOUT DAARVAN, EEN SOLVAAT DAARVAAN OF EEN N-OXIDE DAARVAN, IN HET BIJZONDER EDOXABAN TOSYLAAT; REGISTRATION NO/DATE: EU/1/15/993 20150619
835Luxembourg► SubscribePRODUCT NAME: EDOXABAN, UN DE SES SELS, UN DE SES SOLVATES OU UN N-OXYDE DE CELUI-CI, EN PARTICULIER UN TOSYLATE D EDOXABAN. FIRST REGISTRATION: 20150619
2015000077Germany► SubscribePRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
15/045Ireland► SubscribePRODUCT NAME: EDOXABAN, A SALT THEREOF, A SOLVATIC THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
C0068France► SubscribePRODUCT NAME: EDOXABAN,UN SEL,SOLVATE OU N-OXYDE DE CELUI-CI,EN PARTICULIER L'EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993 20150619
2015 00052Denmark► SubscribePRODUCT NAME: EDOXABAN, HERUNDER EDOXABAN TOSILATE; REG. NO/DATE: EU/1/15/993/001-028 20150623
2015 00052Denmark► SubscribePRODUCT NAME: EDOXABAN, OR A SALT THEREOF, A SOLVATE THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REG. NO/DATE: EU/1/15/993/001-028 20150623
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Accenture
Covington
Baxter
Healthtrust
Moodys
Colorcon
AstraZeneca
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot